IPG 2017 net income drops; Bristol-Myers Squibb inks $1.85 billion deal with Nektar on cancer drug; Merck halts final-stage Alzheimer's drug.
Recruitment for clinical trials has never been easy. New tools and tactics could change that — assuming the sheer volume of information doesn't overwhelm trial organizers.
Novartis Oncology taps Pfizer exec as CEO; healthcare jobs become the largest source of U.S. employment; HHS nominee wary about drug-pricing negotiations
FDA approves first nebulized LAMA COPD treatment; more than 2,000 cancer immunotherapies in development; FDA issues 3D-printing guidance
Technology like this could expand further to form better collaborations between pharma, payers and organized providers.
FDA approves first digital pill; biotech companies race to develop cancer-fighting microbiome drugs; Loxo and Bayer reach $1.55 billion deal for rare cancer drugs
Merck to stop developing hep.-C drugs; FDA approves new Lilly breast-cancer drug; California bill would outlaw co-pay cards
New research suggests that the oft-cited $2.6 billion estimate for bringing a drug to market is significantly overstated.
AstraZeneca to sequence two million genomes; Valeant considering Perrigo CEO as its new chief executive; AMA and PhRMA each spent $6 million on lobbying
Roche's Rituxan generated $7.3 billion in sales in 2015, making it the top-selling orphan drug.